Breast cancer: pertuzumab-related diarrhea is common, but manageable

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • In both metastatic and early-stage HER2+ breast cancer treated with pertuzumab (Perjeta), the incidence of diarrhea is high (28%-72%), but dose-delays or discontinuations resulting from diarrhea are rare.
Why this matters
  • This study gives clinicians and patients information about the freq...